Friday, July 10, 2026
🇺🇸 FDA

Intelligence · Clinical pipeline

Phase III Pipeline Programs

Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Programs 5,427
Sponsors 1,771
Drugs 4,798

Quick answer

NovaPharmaNews tracks 5,427 phase iii pharmaceutical pipeline programs from ClinicalTrials.gov. Late-stage pivotal and registrational clinical programs nearing regulatory submission.

Top sponsors

Pipeline programs

Page 9 of 114

  1. ALXN1210-IgAN-320

    Alexion Europe SAS

    Immunoglobulin A Nephropathy (IgAN)

    phase 3 small molecule active

    1 trial

  2. ALXN1210-IgAN-325

    Alexion Europe SAS

    Immunoglobulin A Nephropathy

    phase 3 small molecule active

    1 trial

  3. ALXN1210-TMA-313

    Alexion Europe SAS

    Hematopoietic stem cell transplant-associated thrombotic microangiopathy

    phase 3 small molecule active

    1 trial

  4. ALXN1720 Placebo Product, Gefurulimab

    Alexion Europe SAS

    Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)

    phase 3 small molecule active

    1 trial

  5. ALXN1840

    Alexion Europe SAS

    Wilson Disease

    phase 3 small molecule terminated

    1 trial

  6. ALXN1850

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  7. ALXN1850 placebo product, ALXN1850

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  8. ALXN1850, ALXN1850 placebo product

    Alexion Europe SAS

    hypophosphatasia

    phase 3 small molecule active

    1 trial

  9. ALXN1850-HPP-303

    Alexion Europe SAS

    Hypophosphatasia

    phase 3 small molecule active

    1 trial

  10. ALXN2040-PNH-303

    Alexion Europe SAS

    Patients with Paroxysmal Nocturnal Hemoglobinuria

    phase 3 small molecule active

    1 trial

  11. ALXN2060

    BridgeBio Oncology Therapeutics

    Symptomatic Transthyretin Amyloid Cardiomyopathy

    phase 3 small molecule completed

    1 trial

  12. ALXN2220-ATTRCM-301

    Alexion Europe SAS

    Adults with Transthyretin Amyloid Cardiomyopathy (ATTR-CM).

    phase 3 small molecule active

    1 trial

  13. AM-PHN-004

    Amneal Pharma Europe Ltd

    Uncomplicated Urinary Tract Infections

    phase 3 small molecule completed

    1 trial

  14. AMAG-FER-CKD-354

    Lacuna Pharma Pty Ltd

    Iron Deficiency Anemia (IDA) in Pediatric Subjects with Chronic Kidney Disease (CKD)

    phase 3 small molecule active

    1 trial

  15. AMAG-FER-IDA-352

    Lacuna Pharma Pty Ltd

    Iron Deficiency Anemia (IDA)

    phase 3 small molecule active

    1 trial

  16. AMG 133, Placebo for Maridebart Cafraglutide

    Amgen

    Chronic Weight Management

    phase 3 small molecule active

    1 trial

  17. AMG 479

    Takeda

    Adenocarcinoma of the Pancreas

    phase 3 small molecule completed

    1 trial

  18. AMG 706

    Takeda

    Non-Small Cell Lung Cancer

    phase 3 small molecule terminated

    1 trial

  19. AMG386 plus PLD

    Amgen

    Fallopian Tube Cancer

    phase 3 small molecule terminated

    1 trial

  20. AMIKACIN

    Pari Pharma GmbH

    Adult patients admitted to intensive care

    phase 3 small molecule active

    1 trial

  21. AMIL/25/Obi-Dys/001

    A.Menarini Australia Pty Limited

    Dyslipidemia at High to Very High Cardiovascular Risk

    phase 3 small molecule active

    1 trial

  22. AMIR-FDC

    Lacuna Pharma Pty Ltd

    Arterial Hypertension

    phase 3 small molecule active

    1 trial

  23. AMPHORA

    Evofem Biosciences

    Contraception

    phase 3 small molecule completed

    1 trial

  24. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Progressive Supranuclear Palsy

    phase 3 small molecule completed

    1 trial

  25. AMX0035

    Amylyx Pharmaceuticals EMEA B.V.

    Amyotrophic Lateral Sclerosis

    phase 3 small molecule active

    5 trials

  26. AMZ001 Diclofenac gel

    Amzell

    Osteoarthritis of Knee

    phase 3 small molecule completed

    1 trial

  27. ANDA219975 + ANDA220011

    Lxo Ireland Designated Activity Company

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  28. APF530

    Heron Therapeutics

    Chemotherapy-induced Nausea and Vomiting

    phase 3 small molecule completed

    1 trial

  29. APF530

    Heron Therapeutics

    Nausea and Vomiting

    phase 3 small molecule completed

    1 trial

  30. APG2575AG301

    Lacuna Pharma Pty Ltd

    Acute myeloid leukemia

    phase 3 small molecule active

    1 trial

  31. APG2575CC301

    Lacuna Pharma Pty Ltd

    Newly Diagnosed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  32. APG2575CG301

    Lacuna Pharma Pty Ltd

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    phase 3 small molecule active

    1 trial

  33. APG2575MG301

    Lacuna Pharma Pty Ltd

    Newly Diagnosed Higher Risk Myelodysplastic Syndrome

    phase 3 small molecule active

    1 trial

  34. APHP 180610

    Pari Pharma GmbH

    Acute Myocardial Infarction

    phase 3 small molecule active

    1 trial

  35. APHP 180610

    Pari Pharma GmbH

    Acute Myocardial Infarction

    phase 3 small molecule active

    1 trial

  36. APHP 200040

    Pari Pharma GmbH

    Acute kidney injury

    phase 3 small molecule active

    1 trial

  37. APHP 230842

    Pari Pharma GmbH

    patients with chronic respiratory insufficiency due to amyotrophic lateral sclerosis.

    phase 3 small molecule active

    1 trial

  38. APHP180560

    Pari Pharma GmbH

    Men and women over 18 years of age with renal failure renal failure stages 3b/4/5, renal transplantation or dialysis and an untreated gout attack

    phase 3 small molecule active

    1 trial

  39. APHP180583

    Pari Pharma GmbH

    Severe Irritable Bowel Syndrome (IBS)

    phase 3 small molecule active

    1 trial

  40. APHP180584

    Pari Pharma GmbH

    patients with acute respiratory failure from undetermined etiology

    phase 3 small molecule active

    1 trial

  41. APHP180587

    Pari Pharma GmbH

    Patients colonized with MDR-GNB

    phase 3 small molecule active

    1 trial

  42. APHP180588

    Pari Pharma GmbH

    early syphilis

    phase 3 small molecule active

    1 trial

  43. APHP180591

    Pari Pharma GmbH

    Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery

    phase 3 small molecule active

    1 trial

  44. APHP180592

    Pari Pharma GmbH

    Diseases [C] - Virus Diseases [C02]

    phase 3 small molecule active

    1 trial

  45. APHP180596

    Pari Pharma GmbH

    antibiotic therapy in Sepsis

    phase 3 small molecule active

    1 trial

  46. APHP180605

    Pari Pharma GmbH

    Excision-autograft surgery in burn patient

    phase 3 small molecule active

    1 trial

  47. APHP180612

    Pari Pharma GmbH

    Dermatomyositis; Baricitinib in patients with relapsing or naïve dermatomyositis.

    phase 3 small molecule active

    1 trial

  48. APHP180668

    Pari Pharma GmbH

    primary sclerosing cholangitis

    phase 3 small molecule active

    1 trial

Frequently asked questions

How many Phase III pipeline programs are in the directory?

5,427 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.